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Abstract
Background: Neuroblastoma (NB) is the second most common solid childhood tumour, an aggressive disease
for which new therapeutic strategies are strongly needed. Tumour necrosis factor-related apoptosis-inducing
ligand (TRAIL) selectively induces apoptosis in most tumour cells, but not in normal tissues and therefore
represents a valuable candidate in apoptosis-inducing therapies. Caspase-8 is silenced in a subset of highly
malignant NB cells, which results in full TRAIL resistance. In addition, despite constitutive caspase-8 expression,
or its possible restoration by different strategies, NB cells remain weakly sensitive to TRAIL indicating a need to
develop strategies to sensitise NB cells to TRAIL. Histone deacetylase inhibitors (HDACIs) are a new class of
anti-cancer agent inducing apoptosis or cell cycle arrest in tumour cells with very low toxicity toward normal
cells. Although HDACIs were recently shown to increase death induced by TRAIL in weakly TRAIL-sensitive
tumour cells, the precise involved sensitisation mechanisms have not been fully identified.
Methods: NB cell lines were treated with various doses of HDACIs and TRAIL, then cytotoxicity was analysed
by MTS/PMS proliferation assays, apoptosis was measured by the Propidium staining method, caspases activity by
colorimetric protease assays, and (in)activation of apoptotic proteins by immunoblotting.
Results: Sub-toxic doses of HDACIs strongly sensitised caspase-8 positive NB cell lines to TRAIL induced
apoptosis in a caspases dependent manner. Combined treatments increased the activation of caspases and Bid,
and the inactivation of the anti-apoptotic proteins XIAP, Bcl-x, RIP, and survivin, thereby increasing the pro- to
anti-apoptotic protein ratio. It also enhanced the activation of the mitochondrial pathway. Interestingly, the
kinetics of caspases activation and inactivation of anti-apoptotic proteins is accelerated by combined treatment
with TRAIL and HDACIs compared to TRAIL alone. In contrast, cell surface expression of TRAIL-receptors or
TRAIL is not affected by sub-toxic doses of HDACIs.
Conclusion: HDACIs were shown to activate the mitochondrial pathway and to sensitise NB cells to TRAIL by
enhancing the amplitude of the apoptotic cascade and by restoring an apoptosis-prone ratio of pro- to anti-
apoptotic proteins. Combining HDACIs and TRAIL could therefore represent a weakly toxic and promising
strategy to target TRAIL-resistant tumours such as neuroblastomas.
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Neuroblastoma (NB) is the most frequent solid extracra-
nial tumour in children and is a major cause of death from
neoplasia in infancy [1]. These tumours are clinically and
biologically heterogeneous, with cell populations differ-
ing in their genetic programs, maturation stage and malig-
nant potential [2]. Clinically, spontaneous regressions
and tumour maturation are frequent in infants or in low
stage tumours, whereas older children often present at
diagnosis with high stage progressive and metastatic dis-
ease and their overall prognosis is poor [2]. Little
improvement in therapeutic options has been made in the
last decade, requiring a urgent need for the development
of new therapies.
Anti-cancer therapies mediate their cytotoxic effect by pre-
dominantly inducing apoptosis in tumour cells. Apopto-
sis may be induced by triggering the death receptors
(extrinsic pathway) or the mitochondria (intrinsic path-
way) leading to the activation of effector caspases [3].
Tumour necrosis factor-related apoptosis-inducing ligand
(TRAIL) is a promising candidate for therapy of many
forms of cancer as it selectively induces cell death in trans-
formed cells, sparing normal tissues [4]. TRAIL mediates
apoptosis by activation of the death receptor pathway. Its
interaction with TRAIL-R1 and -R2 receptors leads to
recruitment of adaptor FADD and initiator caspase-8 to
the DISC, resulting in caspase-8 activation and initiation
of a cell death cascade by direct cleavage of effector cas-
pases [4,5]. The process is positively regulated and ampli-
fied by caspase-3-mediated activation of caspase-8 [6,7],
and/or by parallel activation of the mitochondrial path-
way via caspase-8-dependent cleavage of Bid [8], resulting
in activation of the apoptosome through Bax and Bak oli-
gomerisation and the release of cytochrome-c and Smac/
DIABLO into the cytosol. Conversely, negative regulation
is promoted by the caspase-8 antagonist c-FLIP [9] or by
anti-apoptotic Bcl-2 and Bcl-xL-mediated blockade of
mitochondria activation [10]. In addition, other inhibi-
tors of apoptosis proteins (IAPs), such as cIAP-1/-2 and
XIAP [11] interact with effector caspases, which are neu-
tralized by Smac/DIABLO [3]. Survivin, an other IAP
shown to be over-expressed in most tumours, protects
cancer cells from apoptosis by interacting with Smac/DIA-
BLO.
Resistance to TRAIL-induced apoptosis in various
tumours was described to be caused by the deregulation of
diverse signalling molecules such as down-regulation of
TRAIL-receptors, caspase-8, caspase-10 or Bax, or over-
expression of c-FLIP, Bcl-2, Bcl-xL or survivin [12]. In N-
type NB cells, resistance to TRAIL was attributed to the
down-regulation of caspase-8 expression by hypermethyl-
ation or allelic deletion [13-15], as well as to the down-
regulation of cell surface TRAIL-R1/-R2 expression [16].
Numerous TRAIL resistant tumour cell lines were reported
to be sensitised to TRAIL by combined treatments with
chemotherapeutic agents, cycloheximide (CHX), IFN-γ or
irradiation by diverse cell-type specific mechanisms
[17,18]. We have previously shown that NB cells could be
sensitised to TRAIL by subtoxic doses of chemotherapeu-
tic drugs or CHX by the activation of extrinsic and intrinsic
apoptotic pathways and caspases-dependent cleavage of
XIAP, Bcl-xL and RIP [19]. However as chemotherapeutic
drugs are non-specifically and highly toxic toward non-
tumoral cells, it may be beneficial to develop alternative
and less toxic therapeutic strategies that synergise with
TRAIL.
Histone deacetylase inhibitors (HDACIs) are a new class
of promising anti-cancer agents which inhibit tumour
growth both in vitro and in vivo with very low toxicity
toward normal cells [20]. Recently, several HDAC inhibi-
tors have entered Phase I and Phase II clinical trials and
demonstrate encouraging anti-tumour activity in a variety
of cancer types [21]. The anti-tumour effect of HDACIs
was proposed to result from accumulation of acetylated
histones leading to activation of genes involved in inhibi-
tion of tumour cell growth [20]. Altered activities of his-
tone deacetylases or histone acetyl transferases are indeed
involved in different human cancer [22,23]. HDACIs
mechanism of action appears to involve cell cycle arrest,
induction of apoptosis and differentiation both in vitro
and in vivo [21,22]. The mechanisms of induction of
apoptosis by HDACIs are cell type specific and involve the
activation of the intrinsic apoptotic pathways. HDACIs
can also synergise with TRAIL to induce apoptosis by var-
ious mechanisms depending on tumour types, such as
increased expression of TRAIL-receptors and TRAIL [24-
28], decrease in c-FLIP [24,26,29], Bcl-xL [30], XIAP and
Bcl-2 expression (or activation) [31], or increased forma-
tion of the DISC [26,32].
This is the first report describing the detailed mechanisms
of TRAIL sensitization by HDACIs in neuroblastoma cells.
The analysis of the mechanisms by which the three HDA-
CIs, sodium butyrate (NaB), Trichostatin A (TSA) and
suberoylanilide hydroxamic acid (SAHA) enhance the
action of TRAIL, demonstrates that HDACIs enhance cas-
pases activation and restores a positive ratio between pro-
and anti-apoptotic proteins in favour of apoptosis. In
addition, we demonstrate that HDACIs also potentiate
TRAIL action by increasing the amplitude and the kinetics
of the apoptotic process. The association of TRAIL and
HDACIs, two non-toxic anti-cancer agents, could be of
therapeutic benefit for the treatment of children with NB.Page 2 of 13
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Cell culture and reagents
The caspases-8 positive neuroblastoma cells SH-EP, SH-
EP FADD-DN [33], SH-EP-FLIP [34] and SK-N-AS were
grown in DMEM medium supplemented with 10 % of
FCS, 200 μg/ml gentamicin (Essex Chemie AG). Cells
were incubated with indicated amount of soluble recom-
binant TRAIL (a gift from J. Tschopp) and cross-linking
mouse anti-Flag Ab M2 (Sigma) with a constant ratio of 1/
5 of TRAIL to M2 respectively. Sodium butyrate (Fluka)
was dissolved in H2O and stored at -20°C. SAHA (Biovi-
sion) and TSA (Sigma) were dissolved in DMSO and store
at -20°C. Cells were pretreated 30 min with caspases
inhibitors zVAD-fmk (100 μM, Bachem), zVDVAD-fmk
(50 μM, Calbiochem), zIETD-fmk, zDEVD-fmk, and
zLEHD-fmk (50 μM, R&D systems) before TRAIL or HDA-
CIs treatments.
Cell viability assays
Cells (1–2.5*105/well in 96-well-plates; 100 μl) were
plated 24 h before treatment and incubated with TRAIL
and/or HDACIs for 48 h. Assays were performed in quad-
ruplicates. Viability was measured using the MTS/PMS cell
proliferation kit from Promega according to manufac-
turer's instructions. Percentage of cell viability as com-
pared to untreated controls was calculated.
Measurement of apoptosis by detection of sub-diploid 
population
Cells were harvested by trypsinization, washed twice with
ice-cold PBS, resuspended in 1 ml of ice-cold PBS, and
fixed with 3 ml of 100% ice-cold ethanol for 1 h at 4°C.
For staining with propidium iodide (PI), cells were
washed twice in ice-cold PBS and incubated for at least 30
min at room temperature in 0.2 ml of PBS containing 200
μg/ml RNase A and 10 μg/ml propidium iodide. The
stained cells were analyzed using a FACScan flow cytome-
ter (Becton Dickinson).
Immunoblotting
Whole cell extracts were prepared as already described
[14]. Protein extracts (30–50 μg) were loaded on 12%
SDS-PAGE and transferred on nitrocellulose membranes.
Blots were saturated with 5% skim milk, 0.1 % Tween 20
in TBS and revealed using mouse monoclonal antibodies
to detect caspase-8 (MBL), caspase-2 (Apotech corpora-
tion), caspase-3, caspase-7, XIAP, RIP, cytochrome-c (BD
Pharmingen), AIF (Santa Cruz), β-actin (Sigma). Polyclo-
nal rabbit antibodies were used to detect caspase-9 (Cell
Signaling), Bid, Bcl-xL (BD Transduction Laboratories),
Bim (Imgenex), survivin (R&D systems). Binding of the
first antibody was revealed by incubation with either goat
anti-mouse IgG (Jackson ImmunoResearch) or goat anti-
rabbit IgG (Nordic Immunological Laboratories). Bound
antibodies were detected using the Lumi-light western
blotting substrate (Roche) according manufacturer's
instructions.
Caspases activities
Caspases-8, -2, -3 and -9 protease activities were measured
using the caspases-3, -8, -9 colorimetric protease assay kits
from MBL and caspases-2 colorimetric substrate VDVAD-
pNA from Alexis. Cytosolic lysates were prepared after
TRAIL and/or HDACIs treatments according to manufac-
turer instructions. One hundred μg of protein extracts
were incubated with 200 μM of IETD-pNA, VDVAD-pNA,
DEVD-pNA, and LEHD-pNA colorimetric substrates for 3
h at 37°C. Cell lysates were incubated with 10 μM of cas-
pase inhibitor (zIETD-fmk, zVDVAD-fmk, zDEVD-fmk, or
zLEHD-fmk) for 30 min before addition of the respective
caspase substrate for control experiments. Hydrolysed
pNA was detected using a microtiter plate reader at 405
nm. Background absorbance from cell lysates and buffers
were subtracted from the absorbance of stimulated and
unstimulated samples before calculation of relative cas-
pases activities.
Analysis of mitochondrial transmembrane potential
The drop of mitochondrial membrane potential ΔΨm was
measured by staining the cells with the fluorescent dye JC-
1 [35] according to manufacturer's protocol (Calbio-
chem). Loss of ΔΨm resulting in reduction of red aggre-
gates was measured by flow cytometry using the FL2
channel (550–650 nm) (FACScan, Becton Dickinson).
Results are given in percentage of cells with low ΔΨm
compared to untreated controls.
Cell surface immunostaining
Cells were washed in FACS buffer (RPMI, 10 % FCS, 2 mM
EDTA) and stained with mouse monoclonal antibodies
anti-TRAIL-R1, -TRAIl-R2 and -TRAIL (Alexis), followed
by goat secondary antibody conjugated with FITC (Caltag
laboratory) and analysed by FACScan (Beckton Dinkin-
son).
Transfection with siRNAs
Survivin siRNA targets nucleotides 235–253 of survivin
mRNA 5'-AAGGAGCTGGAAGGCTGGGAGTT-3' and con-
trol siRNA is composed of the inverse sequence 5'-
AAGAGGGTCGGAAGGTCGAGG-3', as described previ-
ously [36]. siRNAs were a gift from the lab of Uwe Zange-
meister-Wittke. 180'000 cells/well were plated in 12 wells
(1 ml) and transfected 8 h later with 100 nM or 25 nM of
siRNAs with 3 μl or 2 μl respectively of
Lipofectamine2000 according to manufacturer's instruc-
tions (Invitrogen). Sixteen h after transfection, cells were
plated in 96 wells (10'000 cells/well) and induced 24 h
later with TRAIL and/or HDACIs for 48 h.Page 3 of 13
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Subtoxic doses of NaB, SAHA and TSA sensitise NB cells to TRAIL-induced cell deathFigure 1
Subtoxic doses of NaB, SAHA and TSA sensitise NB cells to TRAIL-induced cell death. A Sensitisation is depend-
ent on the concentration of TRAIL. SH-EP and SK-N-AS cells were treated with the indicated amount of TRAIL and NaB, 
SAHA or TSA for 48 h. Cell death was measured by MTS/PMS cell proliferation assays. Mean values of three or two independ-
ent experiments are shown for SH-EP or SK-N-AS cells, respectively. B Subtoxic doses of NaB, SAHA and TSA sensitise NB 
cells to TRAIL-induced cell death. Sub-G1 apoptotic cells were detected by the propidium staining method after stimulation for 
16 h or 48 h with 1 mM of NaB, 2.5 μM of SAHA or 0.5 μM of TSA in absence or in presence of TRAIL (25 ng/ml) and M2 (125 
ng/ml). C Subtoxic doses of NaB, SAHA and TSA sensitise NB cells to TRAIL-induced cell death. Sensitisation is dependent on 
the concentration of HDACIs. SH-EP cells were treated with TRAIL 50 ng/ml and M2 (250 ng/ml) and SK-N-AS cells with 
TRAIL 100 ng/ml and M2 (500 ng/ml), and indicated amount of NaB, SAHA or TSA for 48 h.
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HDACIs strongly sensitise caspases-8 positive NB cell lines 
to TRAIL-induced apoptosis
We have previously shown that caspases-8 positive NB
cells are weakly sensitive to TRAIL and could be sensitised
by subtoxic concentrations of chemotherapeutic drugs
such as doxorubicin or cisplatin [19]. Here we analysed
the ability of three different HDACIs belonging to two
structural classes, the short-chain fatty acid NaB and the
hydroxamic acids SAHA and TSA to sensitise these NB
cells to TRAIL-mediated apoptosis. Treatments with sub-
toxic concentrations of NaB, SAHA and TSA highly
increased TRAIL-induced apoptosis in SH-EP cell line as
analysed by proliferation assays (Fig. 1a) or by the propid-
ium iodide staining method (Fig. 1b). SK-N-AS cells,
which are more resistant to TRAIL-induced apoptosis,
could also be strongly sensitised to TRAIL by HDACIs (Fig.
1a). Potentiation of cell death by co-treatment with TRAIL
and HDACIs was dependent on both the concentration of
TRAIL and HDACIs (Fig. 1a and 1c).
In contrast, HDACIs could not sensitise NB cells to low
doses of classical chemotherapeutic drugs, such as Doxo-
rubicin, Taxol, Cisplatin or Etoposide, except for a very
weak sensitisation observed when DOX was combined
with TSA (data not shown). In addition, HDACIs could
not overcome the resistance of caspases-8 positive NB
cells to Fas ligand (data not shown), which could in con-
trast be sensitised by shRNAs-mediated downregulation
of c-FLIPL [34].
Sensitisation to TRAIL by HDACIs requires the integrity of 
the receptor pathway, without involving TRAIL-receptors 
expression
The contribution of the death receptor pathway in this
sensitisation mechanism was analysed using SH-EP cells
over-expressing a FADD dominant-negative protein
(FADD-DN), lacking the death effector domain required
for caspase-8 recruitment to the DISC [33]. SH-EP-FADD-
DN were completely resistant to TRAIL and could not be
re-sensitised to TRAIL by co-treatment with subtoxic doses
of NaB, SAHA or TSA (Fig. 2a). In addition, SH-EP cells
over-expressing c-FLIPL, and caspase-8/-10 negative N-
type NB cells could not be sensitised to TRAIL by com-
bined treatments with TRAIL and HDACIs (data not
shown). These findings indicate that the integrity of the
TRAIL-receptor pathway is necessary for TRAIL sensitisa-
tion by NaB, SAHA and TSA.
To analyse the detailed mechanisms by which these HDA-
CIs enhance the action of TRAIL, the cell surface expres-
sion of TRAIL and the TRAIL-receptors was measured by
FACS. Indeed, recent studies have described that HDACIs
induced the expression of TRAIL and TRAIL-receptors in
leukaemia cells, breast and colon cancer cells [24-28],
Sensitisation by HDACIs to TRAIL requires an intact TRAIL r ceptor pathwayFigure 2
Sensitisation by HDACIs to TRAIL requires an intact 
TRAIL receptor pathway. A SH-EP and SH-EP-FADD-
DN cells were treated 48 h without TRAIL or with TRAIL 
(50 ng/ml) and M2 (250 ng/ml) in the presence or absence of 
NaB (1 mM), SAHA (2.5 μM) or TSA (0.5 μM).B No induc-
tion in cell surface expression of TRAIL and TRAIL receptors 
induced by HDACIs in NB cells. SH-EP cells treated for 24 h 
with NaB (1 mM), SAHA (2.5 μM) or TSA (0.5 μM) were 
incubated with antibody against TRAIL-R1, TRAIL-R2 and 
TRAIL (thick line) or without primary antibody (thin line) and 
then with a FITC labelled secondary antibody.
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HDACIs and TRAIL induce caspases-dependent apoptosisFigure 3
HDACIs and TRAIL induce caspases-dependent apoptosis. A SH-EP cells were uninduced (no) or induced for 48 h by 
TRAIL (25 ng/ml) and M2 (125 ng/ml) (T) and NaB (1 mM), SAHA (2.5 μM) or TSA (0.5 μM), without caspases inhibitors, or 
with zIETD-fmk, zDEVD-fmk, zLEHD-fmk, zVDVAD-fmk or zVAD-fmk. Mean values of three representative experiments are 
shown. B Caspases cleavage is increased by simultaneous treatments with TRAIL and HDACIs. SH-EP cells were untreated 
(no) or treated with TRAIL (25 ng/ml) and M2 (125 ng/ml) (T) and/or NaB (1 mM), SAHA (2.5 μM) or TSA (0.5 μM) for 16 h. 
Whole cell extracts were analysed by immunoblotting for the cleavage of caspases-8, -2, -9, -3 and -7, and Bid. β-actin was used 
as loading control. Percentage of apoptotic cells (sub-G1 population) as analysed by the PI staining method after 16 h of treat-
ments are indicated. C Caspase-3-like activities were induced by TRAIL/HDACIs co-treatments. Hydrolysis of DEVD-pNA was 
measured in SH-EP cells unstimulated (no) or treated with TRAIL (T) and/or NaB, SAHA or TSA for 16 h as in Fig. 3b. The cas-
pase-3-like activities of stimulated cells, relative to unstimulated cells are indicated. The caspase-3/-7 inhibitor DEVD-fmk was 
used as control to inhibit hydrolysis of DEVD-pNA.
BMC Cancer 2006, 6:214 http://www.biomedcentral.com/1471-2407/6/214while other reports have shown no changes in the expres-
sion level of DR4, DR5 and DcR2 in melanoma and lym-
phoma cells [31,37]. No increase in the cell surface
expression of TRAIL, TRAIL-R1 and TRAIL-R2 and the
decoy receptor TRAIL-R3 was observed in SH-EP and
CA2E NB cells after 24 h of treatment with sub-toxic doses
of NaB, SAHA or TSA (Fig. 2b and data not shown). These
results indicate that the sensitising effect of HDACIs on
NB cells acts downstream of the death receptors.
Activation of apoptotic proteins
To understand the mechanisms of sensitisation to TRAIL-
mediated apoptosis by HDAC inhibitors, the involvement
of caspases was analysed using caspases inhibitors. SH-EP
cells were strongly protected from apoptosis induced by
combined treatment with TRAIL and HDACIs by the cas-
pase-8 (zIETD-fmk), the caspase-3/-7 (zDEVD-fmk), the
caspase-9 (zLEHD-fmk), the caspase-2 (zVDVAD-fmk)
protease inhibitors and the pan-caspases inhibitor zVAD-
fmk (Fig. 3a). This demonstrates that HDACIs-mediated
sensitisation to TRAIL is caspases-dependent.
The extent of caspases activation induced by simultaneous
addition of TRAIL and HDACIs was further analysed by
immunoblotting in SH-EP cells. Co-incubation with
TRAIL and NaB, SAHA or TSA for 16 h increased the cleav-
age of procaspases-8, -2, -3, -7 and -9, compared to treat-
ment with TRAIL alone (Fig. 3b). The observed decrease of
Bid was also enhanced by combined treatments (Fig. 3b).
This resulted in Bid activation by caspases dependent
cleavage as further depicted in figure 5d. In contrast, sub-
toxic doses of HDACIs alone failed to induce caspases
activation or changes in the steady-state level of procas-
pases-8, -2, -3, -7 and -9, Bid or FADD (Fig. 3b and data
not show).
To confirm the increased activation of caspases by com-
bined treatment, the caspase-3-like activity was measured
in SH-EP cells. The relative caspase-3-like activities in
lysates of cells treated with TRAIL and NaB, SAHA or TSA
were superior to that of cells treated with TRAIL alone,
whereas no hydrolysis of DEVD-pNA was measured in
lysates from cells treated with HDACIs alone (Fig. 3c).
These results confirm that the decrease in caspases-3 and -
7 as observed in Fig. 3b, results from caspases activation
rather than on deregulation of the pro-caspase expression
level.
HDACIs increase the magnitude of caspases activation
The kinetic of caspases cleavage was then analysed by a
time-course experiment. Results show that combined
treatments with TRAIL and SAHA increased the cleavage
of Bid and procaspases-8, -2 and -3, as cleavages became
apparent after 8 h of treatment with TRAIL and SAHA,
while only weak cleavages were observed at 8 h with
TRAIL alone (Fig. 4a). Similar results were obtained with
TRAIL and NaB, although a faster kinetic of activation was
observed (data not shown). Then, the kinetic and the
extent of caspases-8, -3/7, -2 and -9 activation was meas-
ured using colorimetric caspases substrates. Interestingly,
the maximal level of caspases activation was reached after
8 h treatment, as no further increase was observed after 16
h (Fig. 4b). In addition, the extent of caspases activities
induced by combined treatments was higher than that
induced by TRAIL alone. These analyses suggest that HDA-
Time-course analysis of caspases activationF gure 4
Time-course analysis of caspases activation. A SH-EP 
cells were unstimulated (no) or stimulated with TRAIL (25 
ng/ml) and M2 (125 ng/ml) (T) alone or in combination with 
SAHA (2.5 μM) for 2, 8 or 16 h. Whole cell extracts were 
analysed by immunoblotting for the cleavage of caspases-8, -
2, -3, and Bid. β-actin was used as loading control. B Time-
course analysis of caspases activation. Caspases-8, -2, -3/7 
and -9 activities were measured in lysates of SH-EP cells 
treated as in a) by measuring the hydrolysis of their respec-
tive caspases colorimetric substrates. Caspases activities of 
stimulated cells, relative to unstimulated cells are indicated.
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Activation of the mitochondrial signalling pathwayFigure 5
Activation of the mitochondrial signalling pathway. A SH-EP cells were untreated (no) or treated with TRAIL (50 ng/
ml) and M2 (250 ng/ml) (T) and/or NaB (1 mM), SAHA (2.5 μM) or TSA (0.5 μM) for 20 h. The loss of ΔΨm was measured 
using the fluorescent probe JC-1. The percentage of cells with low ΔΨm is indicated. B Simultaneous treatments with TRAIL 
and HDACIs induce inactivation of anti-apoptotic proteins. SH-EP cells were treated as described in Fig. 3b. Percentage of 
apoptotic cells (sub-G1 population) as analysed by the PI staining method after 16 h of treatments are indicated. C Time-
course analysis of anti-apoptotic protein cleavage. SH-EP cells were treated as in Fig. 4a. D Co-treatments with TRAIL and 
HDACIs induce caspases-dependent cleavages of pro- and anti-apoptotic proteins. SH-EP cells were untreated or treated with 
TRAIL (25 ng/ml) and M2 (125 ng/ml), or with TRAIL (T)+NaB (1 mM), T+SAHA (2.5μM) or TSA (0.5 μM) in the presence or 
absence of zVAD for 16 h. b, c, and d. Whole cell extracts were analysed by immunoblotting for the presence of different pro- 
and anti-apoptotic proteins. β-actin was used as loading control.
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BMC Cancer 2006, 6:214 http://www.biomedcentral.com/1471-2407/6/214CIs sensitise NB cells to TRAIL-induced apoptosis by
increasing the extent of caspases activation and thereby
enhancing the extent of the apoptotic process.
HDACIs increase the activation of the mitochondrial 
pathway induced by TRAIL
The observation of an increased cleavage of Bid and cas-
pase-9, as well as the protection by the caspase-9 inhibitor
from cell death induced by co-treatment with TRAIL and
HDACIs, suggested the involvement of the mitochondrial
apoptotic pathway. To analyse this hypothesis, we meas-
ured the disruption of the transmembrane mitochondrial
potential (ΔΨm) using the fluorescent dye JC-1 in SH-EP
cells after TRAIL/HDACIs treatments. TRAIL alone
induced a drop of the ΔΨm in 35% of the cells after 20 h
of induction, whereas co-treatments with NaB, SAHA or
TSA highly increased the number of cells with a reduced
ΔΨm (60%, 59% and 79 %, respectively) (Fig. 5a). No
reduction of the ΔΨm was observed with cells treated with
NaB or SAHA alone, while a weak loss of ΔΨm was found
in cells treated with TSA (Fig.5a). Combined treatments
also increased the release of cytochrome c and AIF from
the mitochondria into the cytosol (data not shown).
These results indicate that co-treatments with HDACIs
increased the activation of the mitochondrial signalling
pathway induced by TRAIL.
TRAIL/HDACIs co-treatments induce caspases-dependent 
inactivation of anti-apoptotic proteins
The stability of several pro- and anti-apoptotic proteins
was then analysed in SH-EP cells induced by TRAIL and
NaB, SAHA or TSA. A strong decrease in the amount of
BimEL was observed after 16 h of combined treatments,
whereas TRAIL alone induced only a weak reduction of
BimEL expression level (Fig. 5b), while BimL and BimS were
not detected in SH-EP cells (data not shown). In addition,
co-administration of TRAIL and HDACIs increased the
down-regulation of the anti-apoptotic proteins XIAP, Bcl-
xL, survivin, and RIP, compared to TRAIL alone (Fig. 5b
and 5c). Interestingly, the kinetic of inactivation of anti-
apoptotic proteins was accelerated by the co-treatment
with TRAIL and HDACIs. The cleavage of XIAP and the
down-regulation of Bcl-xL and survivin observed after 8 h
of treatment with TRAIL and SAHA was stronger than after
16 h with TRAIL alone (Fig. 5c). Similar results were
obtained with TRAIL and NaB (data not shown). Moreo-
ver, the kinetic of inactivation of anti-apoptotic proteins is
similar to that of caspases activation by proteolytic cleav-
ages (Fig. 4a).
We have previously shown that the down-regulation of
XIAP, Bcl-xL and RIP induced by TRAIL and chemothera-
peutic drugs was caspases-dependent [19]. To analyse if
the reduction of the anti-apoptotic proteins XIAP, Bcl-xL,
survivin, and RIP induced by co-treatments with TRAIL
and HDACIs is likewise caspases-dependent, SH-EP cells
were treated with TRAIL and NaB, SAHA or TSA in the
presence of the pan-caspases inhibitor zVAD. As shown in
figure 5d, the cleavage of XIAP, and the inactivation of Bcl-
xL, survivin, and RIP were protected by the addition of
zVAD (Fig. 5d). Similarly, the activation of Bid and cas-
pase-3 induced by TRAIL and HDACIs were protected by
zVAD (Fig. 5d). These results indicate that sensitisation to
TRAIL by low doses of HDACIs increases the caspases-
dependent cleavages and inactivation of anti-apoptotic
proteins. In addition, the amount of BimEL was increased
in the presence of zVAD indicating that the down-regula-
tion observed by combined treatment was also mediated
by caspases-dependent cleavage (Fig. 5d).
Down-regulation of survivin sensitise NB cells to HDACIs
Survivin is over-expressed in most human cancers includ-
ing NB and was shown to be involved in inhibition of
apoptosis in tumour cells [38]. In addition, down-regula-
tion of survivin by siRNAs was shown to sensitise NB cells
to TRAIL-induced apoptosis [39]. As survivin steady state
level is reduced by co-treatment with TRAIL and HDACIs,
we explored its participation in HDACIs-mediated sensiti-
sation to TRAIL. In this aim, survivin expression, was
down-regulated in SH-EP cells by RNA interference using
survivin siRNAs [36]. As shown in figure 6a, survivin
expression level was significantly reduced by survivin
siRNA as compared to cells transfected with
lipofectamine2000 or control siRNA. The effect of sur-
vivin silencing was analysed by proliferation assay (Fig.
6b). Results show that reduction of survivin expression
with 100 nM siRNAs sensitised NB cells to TRAIL alone, to
low doses of HDACIs as well as to combined treatments
with weak doses of TRAIL and HDACIs (Fig. 6b). Similar
results were observed with 25 nM of survivin siRNAs (data
not shown). These results indicate that down-regulation
of survivin induced by HDACIs and TRAIL may account at
least in part to the sensitising effect of HDACIs to TRAIL-
induced cell death.
Discussion
The present study demonstrates that simultaneous admin-
istration of TRAIL and subtoxic doses of HDACIs strongly
potentiates the triggering of apoptotic cascade in NB cells.
The detailed analysis of the mechanisms of sensitisation
reveals that the increase in cell death is mediated by the
enhanced activation of the caspases cascade and the pro-
apoptotic protein Bid, concomitant with the down-regula-
tion of the anti-apoptotic proteins RIP, Bcl-xL, XIAP, and
survivin in a caspases-dependent manner.
Stimulation of the death receptor pathway through
enhancement of death receptor expression is one mecha-
nism of sensitisation to TRAIL by HDACIs. Several recent
reports have shown that the expression of TRAIL or TRAIL-Page 9 of 13
(page number not for citation purposes)
BMC Cancer 2006, 6:214 http://www.biomedcentral.com/1471-2407/6/214receptors was induced by HDAC inhibitors in leukaemia
cells, breast and colon cancer cells [24-28], while other
studies have reported no change in the expression level of
DR4, DR5 and DcR2 in melanoma and lymphoma cells
[31,37]. We show here that unlike chemotherapeutic
drugs, Doxorubicin, Cisplatin, Etoposide or Taxol which
up-regulate the cell surface expression of TRAIL-R2 in NB
cells [19], HDACIs did not influence any of TRAIL-R1,
TRAIL-R2 and TRAIL cell surface expression in NB cells,
indicating that sensitisation to TRAIL-induced apoptosis
by HDACIs occurs at least partly by different mechanisms.
Several studies reported a change in the expression level of
proteins involved in the extrinsic apoptotic pathway such
as FADD [24] and FLIP [24,26,29]. No change in the
steady state level of caspases-8, -2, -3, -7 and -9, Bid, FADD
SiRNAs-mediated down-regulation of survivin expressionFigure 6
SiRNAs-mediated down-regulation of survivin expression. A Whole cell extracts of SH-EP cells transfected for 40 h 
with lipofectamine2000 alone (lipo), with survivin siRNA (25 or 100 nM), control siRNA (100nM), or untransfected (no) were 
analysed by immunoblotting for the presence of survivin and β-actin as loading control.B Survivin down-regulation by siRNAs 
sensitise NB cells to HDACIs. SH-EP cells were untransfected (no), transfected with lipofectamine 2000 (lipo) alone or with 
survivin siRNA (100 nM) or control siRNA (100 nM), and treated 40 h after transfection with the indicated amounts of NaB 
(mM), SAHA, TSA (μM) and TRAIL (ng/ml). Cell death was measured by MTS/PMS cell proliferation assays.
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BMC Cancer 2006, 6:214 http://www.biomedcentral.com/1471-2407/6/214or FLIP was detected after stimulation with subtoxic doses
of NaB, SAHA or TSA in NB cells. Nevertheless, as previ-
ously reported in leukaemia cells [31], the death receptor
pathway is involved in the synergistic induction of apop-
tosis by simultaneous treatment with TRAIL and HDACIs
in NB cells. Indeed, following over-expression of a FADD-
DN protein or c-FLIPL, NB cells became fully resistant to
TRAIL, which could not be rescued by co-treatments with
HDACIs.
In accordance with previous reports [25,26,32,37,40] we
demonstrate that HDACIs sensitised NB cells to TRAIL by
enhancing the cleavage-mediated activation of the cas-
pases cascade and Bid, while no cleavage was observed
with subtoxic doses of HDACIs alone. The enhanced
apoptosis induction was caspases-dependent as caspases
inhibitors completely abolished NB cell death. Interest-
ingly, TRAIL and HDACIs co-treatments also increased the
amplitude of caspases activation. Indeed, a higher level of
caspases activities was reached with combined treatment
compared to TRAIL alone. This suggests that HDACIs sen-
sitise NB cells to TRAIL-induced apoptosis by enhancing
the extent of caspases activation and thereby increasing
the magnitude of the apoptotic process.
In addition, the simultaneous addition of TRAIL and
HDACIs synergistically affected the mitochondrial path-
way as evidenced by the enhanced drop of ΔΨm, the
increased caspases-9 activation and cytochrome c and AIF
release into the cytosol. This suggests that HDACIs may
also act at the level of the mitochondria to sensitise NB
cells to TRAIL, as previously reported with other tumour
cell lines [24,31,40].
The modulation of the intracellular ratio between pro-
and anti-apoptotic proteins could be an other mechanism
of HDACIs potentiation to TRAIL-induced apoptosis,
which could occur by the increased activity of pro-apop-
totic proteins and/or by the down-regulation of anti-
apoptotic proteins. The BH3-only protein BimEL was
reported to be increased by subtoxic doses of TSA and
depsipeptide in CCL and Jurkat cells [32]. Here we show
that in NB cells BimEL protein level was reduced by treat-
ment with TRAIL and further decreased by co-administra-
tion of HDACIs. This was due to caspases-dependent
cleavage as the down-regulation of BimEL was protected by
zVAD. Interestingly, the activation of BimEL by caspases-3-
dependent cleavage was described to induce a positive
feedback amplification of the apoptotic signal by enhanc-
ing the affinity of BimEL to Bcl-2 [41]. Therefore, in NB
cells BimEL may be activated by caspases-mediated cleav-
age following combined treatment and such BimEL activa-
tion may participate to TRAIL potentiation by HDACIs
through the amplification of the apoptotic signal. In addi-
tion, we observed the reduction of the anti-apoptotic pro-
tein Bcl-xL following combined treatments. Hence, the
increase of the BimEL /Bcl-xL ratio could enhance mito-
chondrial permeability leading to the release of pro-apop-
totic factors.
The caspases-dependent down-regulation of anti-apop-
totic proteins such as XIAP and Bcl-2 [31] and the role of
the down-regulation of Bcl-xL [30] by co-treatment with
TRAIL and HDACIs were previously described. In an other
report it was shown that the reduction of c-FLIP, Bcl-xL,
Bcl-2, and XIAP expression induced by subtoxic doses of
the HDACI LAQ824 was independent on proteasome or
caspases activity [26]. In contrast, we demonstrate here
that the steady state level of RIP, Bcl-xL, XIAP and survivin
in NB cells was reduced by caspases-dependent cleavages
mediated by co-treatments with TRAIL and HDACIs.
Interestingly, both the level and the timing of down-regu-
lation of anti-apoptotic proteins were increased by com-
bined treatments compared to TRAIL alone. The
concomitant caspases-dependent down-regulation of the
anti-apoptotic proteins RIP, Bcl-xL, XIAP, and survivin,
and the activation of the pro-apoptotic proteins Bid and
probably BimEL increased the ratio between pro- and anti-
apoptotic proteins and therefore lowered the threshold of
apoptotic signal and contributed to the sensitising effect
of HDACIs to TRAIL-induced apoptosis.
We have previously shown that RIP, Bcl-xL, and XIAP were
down-regulated by caspases-dependent cleavages upon
co-treatment with TRAIL and chemotherapeutic drugs,
while the steady state level of survivin was not affected, in
contrast to co-treatment with TRAIL and HDACIs [19].
This indicates that HDACIs and chemotherapeutic drugs
contribute through different ways to TRAIL-induced
apoptosis. The reduction of survivin expression mediated
by siRNAs results in an increased the sensitivity threshold
of NB cells to HDACIs and/or TRAIL. This suggests that
the down-regulation of survivin induced by higher doses
of HDACIs and TRAIL plays a role in the sensitising effect
of HDACIs to TRAIL.
Conclusion
The potentiation by HDACIs to TRAIL-induced apoptosis
may be caused by stimulation of the apoptotic cascade
through increased activation of both the extrinsic and the
intrinsic apoptotic pathways induced by TRAIL and HDA-
CIs, respectively. The apoptotic signal is further enhanced
by the caspases-dependent activation of pro-apoptotic
proteins such as Bid and Bimel and inactivation of anti-
apoptotic proteins such as XIAP, Bcl-xL, RIP, and survivin.
It results a change in the equilibrium of pro- to anti-apop-
totic molecules that lowers the cell death threshold and
strongly favours apoptosis.Page 11 of 13
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BMC Cancer 2006, 6:214 http://www.biomedcentral.com/1471-2407/6/214These findings may have important implications for the
use of TRAIL in cancer therapeutic using recombinant sol-
uble TRAIL. As HDACIs strongly enhance the apoptotic
action of TRAIL even at low concentrations, HDACIs may
be used in combination with TRAIL to reduce the doses of
TRAIL required for inhibition of tumour growth. Recently,
several HDAC inhibitors have entered Phase I and Phase
II clinical trials and are demonstrating encouraging anti-
tumour activity in a variety of cancer types (21). The com-
bination of TRAIL and HDACIs may therefore be an inter-
esting and soft inoffensive new anti-tumour strategy
particularly relevant in the treatment of children with
highly malignant neuroblastoma.
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